Tempus AITEM reached an important technical milestone, with its Relative Strength (RS) Rating moving into the 90-plus ...

Tempus AI TEM expects full-year 2025 revenues of $1.25 billion (up from the previous $1.24 billion guidance), which represents approximately 80% annual growth. The company also expects adjusted EBITDA ...

Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the ...

Key Takeaways Tempus AI stock shows 15–32% upside potential based on analyst forecasts.The company leads in using artificial ...

One of Wood's favorite AI stocks has been criticized by CNBC host Jim Cramer multiple times in 2025, including this week.

Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter ...

Healthcare is the most underappreciated AI beneficiary,” said Ark Invest CEO Cathie Wood in a recent statement that’s ...

The global AI infrastructure market is projected to grow at a CAGR of 29.1%, reaching $356.14 billion by 2032 from $36.59 billion in 2023, according to Fortune Business Insights.

Personalis and Tempus AI are adding colorectal cancer as a new indication to their existing commercialization agreement.

Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market ...